InvestorsHub Logo
Post# of 251721
Next 10
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

Re: genisi post# 142518

Thursday, 05/24/2012 10:16:12 AM

Thursday, May 24, 2012 10:16:12 AM

Post# of 251721
Importantly for MNTA investors, Teva did not lower its guidance for 2012 Copaxone sales; rather Teva’s guidance remains at $3.8B, which suggests US Copaxone sales of approximately $2.6B (#msg-75407657). The $2.6B figure assumes no generic entry in the market, of course.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.